InflaRx N.V. (IFRX) vs ProQR Therapeutics N.V. (PRQR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, gaining 4.1% versus a loss of 33.5%. Over five years, IFRX leads with a -38.1% price change compared with -80.1% for PRQR. InflaRx N.V. is the larger company by market cap ($225.5 million vs $221.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | PRQR |
|---|---|---|
| Share price | $1.53 | $1.57 |
| Market cap | $225.47M | $221.56M |
| 1-day change | -1.92% | -3.68% |
| YTD return | +51.49% | -22.28% |
| 1-year return | +4.08% | -33.47% |
| 5-year return | -38.06% | -80.08% |
| EPS (TTM) | $-0.58 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $3.10 |
| 52-week low | $0.798 | $1.33 |
| Distance from 52-week high | -48.12% | -49.35% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +401.96% | +395.54% |
| Average volume | 798.72K | 796.41K |
| Shares outstanding | 147.37M | 141.12M |
| Employees | 65 | 186 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed PRQR by 37.6 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
IFRX vs PRQR FAQ
Which is bigger, InflaRx N.V. or ProQR Therapeutics N.V.?
InflaRx N.V. (IFRX) is larger, with a market capitalization of $225.47M compared with $221.56M for ProQR Therapeutics N.V. (PRQR).
Which stock has performed better over the past year, IFRX or PRQR?
IFRX returned +4.08% over the past 12 months, compared with -33.47% for PRQR (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and ProQR Therapeutics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.